Skip to main content
Premium Trial:

Request an Annual Quote

Idaho Technology Changes Name to BioFire Diagnostics

Premium

Idaho Technology said yesterday that it has changed its name to BioFire Diagnostics.

The Salt Lake City, Utah-based company said that the new name more accurately reflects its business strategy and "strong momentum in the marketplace."

BioFire will continue to develop multiplex diagnostic tests for various clinical applications on its FilmArray pathogen detection system. The company's US Food and Drug Administration-approved FilmArray Respiratory Panel is cleared for 20 viral and bacterial respiratory pathogens, eight of which aren't covered by any other FDA-cleared test (PCR Insider, 5/17/2012).

BioFire is also developing FilmArray panels for pathogen identification in blood culture, for which it initiated clinical trials last month (PCR Insider, 7/19/2012). It is also working on panels for gastrointestinal infections, meningitis, and other indications.

The company was also recently awarded a one-year, $262,000 grant from the National Institutes of Health to develop a FilmArray panel to detect pathogens causing pneumonia or other lower respiratory tract infections (PCR Insider, 7/26/2012).

The FilmArray platform integrates sample preparation, amplification, detection, and analysis, and is designed to provide results in about an hour with about two minutes of hands-on time, according to the company. The instrument performs PCR to initially amplify nucleic acids from target pathogens, and uses melt curve analysis for multiplexed detection.

BioFire said that it will continue develop biosurveillance products such as its PCR-based biodetection system RAZOR EX and the FilmArray BioSurveillance System.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.